FDA Medical Device Labeling: Part 801

FDA labeling is broader than the physical label

Device labeling includes the label and relevant accompanying material. Evaluate packaging, instructions, installation and service information, software screens and promotional claims as applicable. The US FDA can regard a device as misbranded when information is false or misleading or required information is missing; FDA's misbranding overview explains the framework.

Start with the authorized intended use, indications, users and use environment. A manufacturer cannot expand the clinical claim simply by changing a website or translating an IFU. Assess the effect on classification and the submission pathway as well as the artwork.

Part 801 and device-specific requirements

21 CFR Part 801 contains general device labeling requirements, with additional rules for particular products and circumstances. Assess required identity and business information, adequate directions, warnings, prominence, language and applicable exemptions. Prescription-device provisions are conditional; an Rx statement alone does not cure inadequate professional instructions or an unsupported indication.

IVD labeling also requires assessment under Part 809, including the intended diagnostic purpose and appropriate instructions, limitations and performance information. Research Use Only and Investigational Use Only labels are tied to the actual product use and distribution circumstances. Adding an RUO statement is not a shortcut for marketing a diagnostic product for clinical decisions.

Symbols, language and electronic information

The FDA symbols rule and FAQ set conditions for using stand-alone symbols to convey required information, including applicable standards recognition and a symbols glossary. ISO 15223-1 familiarity alone does not establish that every symbol can replace text on every label. Confirm the symbol meaning, recognition scope and glossary access.

Assess electronic labeling against the applicable device and user provisions rather than assuming a PDF or QR code universally replaces a physical IFU. Maintain reliable access and version control wherever electronic information is permitted. Review foreign-language content against Part 801 requirements; a multilingual label requires more than adding translated marketing text.

Artwork and evidence release checklist

• Reconcile the device name, model, intended purpose and configuration with the authorized submission.
• Map each required item to the device, packaging or accompanying document and document any applicable exemption.
• Confirm warnings, contraindications, user steps and performance claims against risk, validation and clinical evidence.
• Verify UDI and GUDID consistency, packaging hierarchy and applicable direct-marking duties.
• Approve a controlled label and IFU master, with traceability to translations and released production versions.
• Assess any change for a new submission, record update or other regulatory action before implementation.

Keep labeling controls connected to QMSR and complaint/MDR reporting. A field correction to a warning can affect patient safety, reporting and marketing authorization simultaneously.